19 June 2013
Keywords: dor/dowpharma, sign, development, deal, botulinum, vacc, dor
Article | 08 August 2005
DOR BioPharma has entered into a joint development agreement with fellow USA-based group Dowpharma, a business unit of Dow Chemical, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 August 2005
18 June 2013
© 2013 thepharmaletter.com